Interferon-a Therapy in Chronic Myelogenous Leukemia: Questions Related to the German Randomized Trial

To the Editor:
We read with interest the report of Hehlmann et all in which 133 patients were randomized to interferon-a (IFN-a) therapy (5 X lo6 U/m2/d). The incidence of complete hematologic response. (CHR) was 31% and of complete cytogenetic response was 7%. Their median survival was 5.5 years, which was superior to that of 186 patients treated with busulfan (median survival, 3.8 years; P = .008), but similar to that of 194 patients treated with hydroxyurea (median survival, 4.7 years). The study has raised several important questions.
The first question regards the incidence of CHR with IFN-a therapy, which was considerably lower than that in other studies, including ours, despite similar response criteria (in our studies, normalization of peripheral counts also requires a decrease in platelet counts to <450 X IO3/pL).' The incidences of major and complete cytogenetic responses were inferior to those obtained in our studies of 274 patients treated with IFN-a regimens (Table l) .' A complete cytogenetic response was achieved in 26% of patients (versus 7% in the current study), and a major cytogenetic response was achieved in 38% (versus <lo% in the current study). This is important because survival improvement is noted mostly among patients achieving cytogenetic response at 12 to 24 months3" or a major cytogenetic response at any time.' This is in line with the concept that achieving minimal tumor burden (complete or major cytogenetic response) in chronic myeloid leukemia ( C m ) prolongs survival. Thus, studies in which the incidence of major cytogenetic response is low (eg, < 10%. as in this study) may not be associated with survival prolongation over conventional (hydroxyurea) therapy in the total population.
The second question regards why there are such differences in response rates with the same IFN-a therapy? Several factors may account for the differences. These factors include (1) the actual dose schedule of IFN-a delivery and the expertise of the treating physicians and (2) different population characteristics. A physician "learning curve" may exist with newer therapies, and physicians may be reluctant to use the investigational treatment (eg, IFN-a) at the full intended dose or even at all, particularly when it is more ;p% cumbersome (subcutaneous), more toxic, and more expensive than the conventional therapy. This is reminiscent of the early investigations with Adriamycin and cisplatin that concluded that these agents were too toxic for current oncology practice, as judged by panels of experts (both agents are currently the backbone of solid tumor therapeutic programs). As discussed by Hehlmann et al,' the actual dose of INF-a delivered was 4.85 X lo6 U/m2/d only in the first 4 weeks, but declined to about 2 X IO6 U/mz/d in the next 60 months. The median dose of IFN-a delivered was 5 X IO6 U/m2/d in our studies in the first 3 years and 4.28 X lo6 U/mz/d in in the Italian study: ie, about 2 times higher than the dose in the German trial. A dose-response curve has been shown in our studies and in those by other^.^"
The third question regards the prognostic discrimination of different patient subgroups with IFN-a therapy. Unlike the results of Hehlmann et al.' our studies have shown significant prognostic discrimination with IFN-a therapy for both cytogenetic response and for survival (Table 2) , which is in line with the results of the Italian group! The data also show that the differences in cytogenetic response rates cannot be accounted for only by the different population characteristics, because the range of major cytogenetic response rates, even among the worst risk group (14% to 26%). was still superior to that achieved in the total study group of Hehlmann et al' (<lo%).
The fourth question regards the association between cytogenetic response and survival. In our study, a cytogenetic response at 12 months was associated with significant survival improvement by landmark analysis; a major cytogenetic response at any time, entered as a time-dependent variable, was also associated with a significant survival improvement by multivariate analysis.' Similar findings were reported by the Italian investigators: Although the current study does not show a significant difference in outcome by cytogenetic response, the number of patients involved is too small (15 cytogenetic responders and 69 nonresponders); a trend for better outcome among cytogenetic responders is noted (Fig 5B in Hehlmann et a]'; 4-year survival rates 100% with cytogenetic response v ~6 6 % without a cytogenetic response; P = .2). With the number of patients studied, there is a high probability of detecting a falsenegative outcome, as may have happened in this analysis.
Finally, although recognizing the difficulties of performing cytogenetic studies in cooperative groups, we believe that the value and frequency of cytogenetic studies should be emphasized. In the German trial, 49 of 133 patients (37%) did not undergo any cytogenetic studies; the others underwent cytogenetic analysis only every 12 months (median number of studies, 2). This would underestimate For personal use only. on September 14, 2017. by guest www.bloodjournal.org From the incidence of cytogenetic response and categorize cytogenetic responders in the nonresponse category, thus falsely improving the survival outcome of nonresponders compared with responders. Because cytogenetic response is a major prognostic determinant with IFN-a therapy in CML, cytogenetic studies should be performed frequently (every 3 months in the first 2 years and every 4 to 6 months thereafter) and in all patients on such investigational trials.
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